Subscribe To
PYXS / Pyxis (PYXS) Up on Advancing Cancer Therapy Candidates
PYXS News
By Zacks Investment Research
August 21, 2023
Down -15.56% in 4 Weeks, Here's Why You Should You Buy the Dip in Pyxis Oncology, Inc. (PYXS)
Pyxis Oncology, Inc. (PYXS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined more_horizontal
By Zacks Investment Research
July 17, 2023
Pyxis Oncology, Inc. (PYXS) Upgraded to Strong Buy: What Does It Mean for the Stock?
Pyxis Oncology, Inc. (PYXS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. Thi more_horizontal
By Seeking Alpha
June 12, 2023
Pyxis Oncology: A High-Stakes Gambit In The Battle Against Solid Tumors
Pyxis Oncology is developing next-generation therapeutics, including antibody-drug conjugates and immuno-oncology programs, to target solid tumors res more_horizontal
By Zacks Investment Research
May 31, 2023
Pyxis (PYXS) Up on Advancing Cancer Therapy Candidates
Pyxis' (PYXS) shares rise as the company advances its phase I candidates, PYX-106 and PYX-201, for challenging cancer therapies. more_horizontal
By Seeking Alpha
March 27, 2023
Pyxis Oncology: Cashed Up And Entering The Clinic
PYXS has initiated dosing with PYX-201 in a phase 1 study, with preliminary results due in early 2024. PYXS expects to initiate dosing in a phase 1 st more_horizontal
By GlobeNewsWire
June 28, 2022
Pyxis Oncology to Present at H.C. Wainwright Preclinical Cancer Drug Discovery Conference
CAMBRIDGE, Mass., June 28, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), an oncology company focused on developing next-generation the more_horizontal
By GlobeNewsWire
March 22, 2022
Pyxis Oncology to Host Corporate Update Conference Call and Webcast on March 29, 2022
CAMBRIDGE, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset, multi-modality company focused on developing more_horizontal